For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Plecanatide
Illustration for Plecanatide

THE PEPSRADAR ENCYCLOPEDIA

Plecanatide

Guanylate cyclase-C signaling in constipation care

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Plecanatide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Plecanatide?

Plecanatide is an oral peptide medicine used for chronic idiopathic constipation and IBS with constipation in adults.

Biological role or research focus

Guanylate cyclase-C signaling in constipation care.

The adult clinical context and pediatric dehydration warning are central to reading the source.

Role reference: MedlinePlus · Plecanatide ↗

Names you may encounter

Trulance

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Uroguanylin-related GC-C agonist
Main research area
Adult constipation care
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Plecanatide ↗

Quick answers

Is Plecanatide FDA approved?
Yes. Trulance (NDA 208745, approved 2017) for chronic idiopathic constipation and IBS with constipation. Source ↗
Is Plecanatide safe?
Plecanatide is an oral constipation drug that acts in the gut; diarrhea is the main side effect, and it is barred for young children because it caused fatal dehydration in young mice. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Plecanatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Phase 3 constipation study (2017)Human randomized trial1,394 people with chronic idiopathic constipation.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2017

Phase 3 constipation study

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.

Population / model
1,394 people with chronic idiopathic constipation.
Study design
Twelve-week blinded study of two plecanatide groups versus placebo, using daily bowel diaries.
Main finding
Durable complete-spontaneous-bowel-movement response occurred in 21.0% and 19.5% versus 10.2% with placebo. Diarrhea occurred in about 6% versus 1.3%.
Limits & context
A higher response rate does not mean everyone responds. This adult constipation trial does not remove pediatric restrictions or apply to bowel obstruction.

Source: A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

14 registered studies name Plecanatide as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet and 13 completed. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
NCT07723924 · Bausch Health Americas, Inc.
Active, not recruitingPhase 22026-08-18180
The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)
NCT02387359 · Bausch Health Americas, Inc.
CompletedPhase 32014-121054
GCC Agonist Signal in the Small Intestine
NCT05107219 · University of Wisconsin, Madison
CompletedPhase 12022-11-3043
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905 · Bausch Health Americas, Inc.
CompletedPhase 22018-06-30218
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
NCT05151328 · Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
CompletedPhase 32022-03-18648
Long Term Safety Study of Plecanatide
NCT02706483 · Bausch Health Americas, Inc.
CompletedPhase 32016-012272
12-Week Study of Plecanatide for CIC (The CIC3 Study)
NCT01982240 · Bausch Health Americas, Inc.
CompletedPhase 32013-111394
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
NCT03551873 · Bausch Health Americas, Inc.
Completed2018-06-217

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 14 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
Gastroenterology · 2023 Jun · Practice Guideline, Journal Article
Read available full text ↗

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
The American journal of gastroenterology · 2023 Jun 1 · Journal Article, Practice Guideline
Read available full text ↗

Plecanatide. ↗
· 2006 · Review

Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. ↗
The lancet. Gastroenterology & hepatology · 2019 Nov · Journal Article, Research Support, N.I.H., Extramural, Systematic Review, Network Meta-Analysis

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Plecanatide is an oral constipation drug that acts in the gut; diarrhea is the main side effect, and it is barred for young children because it caused fatal dehydration in young mice.

FDA boxed warning

Risk of serious dehydration in children: not for children under 6, and should be avoided under 18. In young juvenile mice, plecanatide caused deaths from dehydration.

Human safety data: FDA label

Safety is established by FDA labeling from large placebo-controlled trials in adults with chronic constipation or IBS with constipation. Very little enters the bloodstream. The label lists no drug interactions, and safety under 18 is not established.

No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

  • Children under 6 years old (risk of serious dehydration)
  • Children and teens aged 6 to 17: label says avoid
  • Known or suspected mechanical bowel obstruction

Serious risks

  • Severe diarrhea
  • Serious dehydration in children

Common side effects

  • diarrhea

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Trulance (plecanatide) prescribing information ↗

Key precautions

Diarrhea, dehydration, bowel-obstruction precautions, and pediatric restrictions are central. Severe diarrhea warrants clinical attention rather than being assumed to be a desirable cleansing effect.

Source: MedlinePlus · Plecanatide ↗

Regulatory status

U.S. FDA approval
Approved
Trulance (NDA 208745, approved 2017) for chronic idiopathic constipation and IBS with constipation. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

Its medication reference describes adult constipation conditions. The trial measures a sustained bowel-response definition rather than an unspecified detoxification or repair effect.

Source: MedlinePlus · Plecanatide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It activates guanylate cyclase-C pathways that support intestinal fluid movement and transit. The desired clinical effect is improved bowel function.

Source: MedlinePlus · Plecanatide ↗

Molecular structure

Plecanatide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 70693500 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • The adult clinical context and pediatric dehydration warning are central to reading the source.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Did every treated participant meet the trial’s responder definition?

No. About one-fifth did, compared with about one-tenth on placebo.

Source: MedlinePlus · Plecanatide ↗

Is it interchangeable with linaclotide?

They act in a related pathway but are different medicines, with their own evidence and instructions.

Source: A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Plecanatide

Download illustration ↓Source record ↗
Plecanatide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.